Jorge Maspero on Muck Rack

Jorge Maspero

Argentina
As seen in: Wiley Online Library, ScienceDirect, The New England Journal of Medicine, The Lancet, Dove Medical Press, European Respiratory Journal, Chest, The Journal of Allergy & Clinical Immunology, Annals of Allergy, Asthma & Immunology, Respiratory Medicine
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jorge

Contact Jorge, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rilzabrutinib for patients with moderate-to-severe asthma with uncontrolled symptoms: a double-blind, placebo-controlled, phase 2 study

|
By Jorge Maspero, Fundación Cidea Allergy
| The Lancet Verified
Get full text access Log in, subscribe or purchase for full access. References 1. Global Initiative for Asthma Global Strategy for Asthma Management and Prevention, 2025 2. GBD Collaborators Global Health Metrics. Asthma—Level 3 cause Lancet. 2020; 3. Ilmarinen, P ∙ Juboori, H ∙ Tuomisto, LE ∙ et al. Effect of asthma control on general health-related quality of life in patients diagnosed with adult-onset asthma Sci Rep. 2019; 9, 16107 4. Wang, Z ∙ Li, Y ∙ Gao, Y ∙ et al.
Open in Who Shared Issue with article?

Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic dermatitis: A population-based cohort study

|
By Jorge Maspero, Megan Hardin, Remy S. Petersen, Danny Cohn
| ScienceDirect Verified
Previous randomized controlled trials have established the efficacy of dupilumab among patients with chronic obstructive pulmonary disease (COPD) treated with triple therapy over 52 weeks of follow-up. This population-based cohort study aimed to explore the long-term safety and effectiveness of dupilumab in patients with COPD. The study included US patients with COPD who were seen between April 2017 and August 2024.
Open in Who Shared Issue with article?

Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study

|
By Leonard B. Bacharier, Jorge Maspero, Alessandro Fiocchi, Remi Gagnon
| The Lancet Verified
Assessment of long-term safety and efficacy of dupilumab in children with asthma (LIBERTY ASTHMA EXCURSION): an open-label extension study - The Lancet Respiratory Medicine
Open in Who Shared Issue with article?
See all 25 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified